Join our LinkedIn PATENTSCOPE users Community Group
Feedback
Settings

Settings

Goto Application

1,073 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/50 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 108
1.WO/2021/207213METHODS TO PREVENT SARS-COV-2 INFECTION AND TREAT COVID-19
WO - 14.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/US2021/025980 Applicant UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED Inventor OSTROV, David A.
Methods of preventing or treating infection by a SARS-CoV-related betacoronavirus are described. The methods include administering to a patient at risk of being infected by a SARS-CoV-related betacoronavirus or suffering from SARS-CoV-related betacoronavirus-related illness a small molecule drug and/or an antibody that binds to the ACE2-SARS interaction domain of either ACE2 or SARS-CoV-2 spike protein. Also described are vaccines comprising S-protein polypeptides corresponding to the ACE-2 interaction domain.
2.3173187METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS
CA - 14.10.2021
Int.Class A61K 31/195
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
 Appl.No 3173187 Applicant UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. Inventor TRIPP, RALPH A.
Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can be therapeutic and/or prophylactic. The amount of probenecid, metabolite or analog thereof, or pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
3.WO/2023/030476IMMUNOGENIC COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST VARIANTS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
WO - 09.03.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/CN2022/116668 Applicant MEDIGEN VACCINE BIOLOGICS CORPORATION Inventor CHEN, Charles
Provided are immunogenic compositions and methods for immunization against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially an immunogenic composition having a recombinant SARS-CoV-2 S protein derived from Beta (B. 1.351) variant and methods using an immunogenic composition derived from SARS-CoV-2 Beta (B. 1.351) variant.
4.WO/2024/026553NOVEL ANTIGENIC EPITOPE AGAINST SARS-COV-2 AND USES THEREOF
WO - 08.02.2024
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/CA2022/051182 Applicant CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL Inventor FINZI, Andrés
The present application discloses antigenic peptides that are recognized by neutralizing anti-SARS-CoV-2 antibodies. Neutralizing antibodies targeting these antigenic peptides are effective against several SARS-CoV-2 variants. Conjugates, vesicles, pharmaceutical compositions and vaccines comprising the antigenic peptides, as well as antibodies recognizing these antigenic peptides, are also disclosed. The antigenic peptides and encoding nucleic acids, conjugates, antibodies or antigen-binding fragments thereof, vesicles, pharmaceutical compositions or vaccines described herein may be used for the prevention and/or treatment of coronavirus infection and/or associated diseases and symptoms, such as SARS-CoV-2 infection and/or COVID-19.
5.3187609IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
CA - 23.12.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
 Appl.No 3187609 Applicant MEDIGEN VACCINE BIOLOGICS CORPORATION Inventor KUO, TSUN-YUNG
Provided an immunogenic composition against severe acute respiratory syndrome coronavirus (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
6.WO/2021/254473IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
WO - 23.12.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
 Appl.No PCT/CN2021/100826 Applicant MEDIGEN VACCINE BIOLOGICS CORPORATION Inventor KUO, Tsun-Yung
Provided an immunogenic composition against severe acute respiratory syndrome coronavirus (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
7.2021290765Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
AU - 23.12.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
 Appl.No 2021290765 Applicant Dynavax Technologies Corporation Inventor CAMPBELL, John D.
Provided an immunogenic composition against severe acute respiratory syndrome coronavirus (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
8.WO/2005/035712METHODS AND COMPOSITIONS FOR INFECTIOUS CDNA OF SARS CORONAVIRUS
WO - 21.04.2005
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
 Appl.No PCT/US2004/023548 Applicant UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Inventor BARIC, Ralph S.
The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.
9.20060240530Compositions of coronaviruses with a recombination-resistant genome
US - 26.10.2006
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
 Appl.No 11334877 Applicant The University of North Carolina at Chapel Hill Inventor Baric Ralph S.

The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.

10.WO/2022/221843METHODS OF INDUCING IMMUNE RESPONSE AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) VARIANTS OF CONCERN
WO - 20.10.2022
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
 Appl.No PCT/US2022/071691 Applicant INOVIO PHARMACEUTICALS INC. Inventor SMITH, Trevor
Disclosed herein are methods of administering and uses of a plasmid encoding residues 19- 1279 of SEQ ID NO: 1, a plasmid comprising nucleotides 55-3837 of SEQ ID NO: 2, pGX9501, INO-4800 drug product, or a biosimilar thereof to induce an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) variant B.1.351, SARS-CoV-2 variant B.1.1.7, SARS-CoV-2 variant P.1, SARS-CoV-2 variant B.1.617.1, SARS-CoV-2 variant B.1.617.2, or SARS-CoV-2 variant B.1.1.529.
# -